Phacilitate Talks episode 3 with Jacob Petersen, Novo Nordisk and Delfi Krishna, GSK

Episode 3: Reducing COGs, Cellular Analytics and Socially Distanced Manufacturing

Phacilitate Talks episode three
In this episode, hosts Anthony Davies and Michael Adeniya get to talk to two cell therapy CMC experts in Delfi Krishna, Director Cell and Gene Therapy Platform: R&D Strategy at GSK and Jacob Peterson, Corporate Vice President Head of Stem Cell R&D with Novo Nordisk.

The discussion tackled cellular analytics, manufacturing and the impact the Covid-19 pandemic is having on both capacity and clinical pipelines. Delfi kicks us off with her company's challenge around managing the cost of goods for autologous therapies...

A special thanks to Jacob for joining us from vacation! 

And here's the link to the European CDMO map mentioned in the video.